MedTrace Logo

Comparing PA Compliance During and After Decompensation in HFP

NCT03914222 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-09-10

No results posted yet for this study

Summary

Pulmonary Artery Compliance measurements will be obtained with the Respirix device in patients with congestive heart failure decompensation. Echocardiogram, weight measurements, and BNP will also be gathered as independent measures of decompensation in the clinic. Pulmonary Artery Compliance measurements will be made daily during the hospital stay. Patients can continue using the device at home for the next 3 weeks. Each patient will serve as their own control and relative changes from their baseline will be recorded for each parameter.

Conditions

  • Congestive Heart Failure
  • Decompensated Heart Failure

Interventions

DEVICE

CardioSpire (Respirix) Device

Patients will blow into the device through a small tube, which analyzes the signals in the airway patterns.

Sponsors & Collaborators

  • Theranova, L.L.C.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-24
Primary Completion
2019-12-31
Completion
2020-02-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03914222 on ClinicalTrials.gov